Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

FDA Approves Perioperative Durvalumab Plus Chemo for Muscle-Invasive Bladder Cancer

March 28th 2025

The FDA approved perioperative durvalumab plus chemotherapy for muscle-invasive bladder cancer.

FDA Expands Indication for Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

March 28th 2025

The FDA has expanded the indication for lutetium Lu 177 vipivotide tetraxetan for use in additional patients with PSMA-positive metastatic castration-resistant prostate cancer.

CHMP Offers Positive Opinion for Perioperative Nivolumab Plus Chemo in Resectable PD-L1+ NSCLC

March 28th 2025

The EMA’s CHMP has recommended the approval of perioperative nivolumab plus chemotherapy in resectable PD-L1–positive non–small cell lung cancer.

Dr Maughan on the Need for Consensus on Treatment Intensification in mHSPC

March 27th 2025

Benjamin L. Maughan, MD, PharmD, discusses the need for improved update of treatment intensification in metastatic hormone-sensitive prostate cancer.

Dr Morgans on Standardizing the Management of Bone/Cardiac Health With Systemic Therapy in Prostate Cancer

March 27th 2025

Alicia Morgans, MD, MPH, discusses the importance of managing bone and cardiac health in patients with prostate cancer receiving systemic therapy.

Dr Park on Individualized First-Line Bladder Cancer Management Options

March 27th 2025

Chandler Park, MD, discusses key factors that facilitate decisions between the available frontline treatment regimens for patients with bladder cancer.

Effective Toxicity Management is Key to Maximizing Benefit With MEK Inhibitors in NF1-Associated PN

March 27th 2025

Christopher L. Moertel, MD, discusses advances and ongoing research in NF1-associated plexiform neurofibromas.

Nirogacestat Provides Long-Term Benefits in Desmoid Tumors

March 27th 2025

Nirogacestat sustained long-term efficacy with acceptable safety in patients with desmoid tumors treated in the phase 3 DeFi trial.

Continued Development of T-Cell–Redirecting Therapies Remains at the Heart of Myeloma Research

March 27th 2025

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights advances in T-cell–redirecting therapies in the space.

TTFields/Paclitaxel Fails to Boost OS in Platinum-Resistant Ovarian Cancer But Shows Potential in Key Subgroup

March 26th 2025

The addition of tumor treating fields to paclitaxel did not lead to a statistically significant overall survival improvement in platinum-resistant ovarian cancer.

Multiple Myeloma Awareness Month: Symptom Recognition and Understanding Precursor Conditions Are Key for Diagnosis

March 25th 2025

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights symptom recognition and precursor conditions for the malignancy.

Nemvaleukin Fails to Show OS Benefit Over Chemotherapy in Platinum-Resistant Ovarian Cancer

March 25th 2025

The development of nemvaleukin in platinum-resistant ovarian cancer will be discontinued based on interim OS data from the phase 3 ARTISTRY-7 trial.

Olvi-Vec Plus Chemo Yields Disease Control in Platinum-Relapsed or -Refractory ES-SCLC

March 25th 2025

Olvi-vec plus chemotherapy led to disease control in extensive-stage small cell lung cancer that was relapsed/refractory to platinum chemotherapy.

Targeted Treatment and Improved Radiation Technologies Offer Advantages in CRC Realm

March 25th 2025

Yufei Liu, MD, PhD, discusses current radiation strategies, including SBRT and IMRT, along with the benefits of radiation therapy in colorectal cancer.

Selection of Frontline CDK4/6 Inhibitors Hinges on Patient Health Status in HR+/HER2– Metastatic Breast Cancer

March 21st 2025

Tanya Gupta, MD, details FDA-approved CDK4/6 inhibitors and considerations for selecting treatment in HR-positive, HER2-negative metastatic breast cancer.

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Based Insights

March 21st 2025

Joshua Feinberg, MD, discusses the role of the Scout AI platform in aiding trial matching and treatment selection in oncology.

FDA Approves PSMA PET Imaging Agent TLX007-CDx for Prostate Cancer

March 20th 2025

The FDA has approved TLX007-CDx as an imaging agent in select patients with prostate cancer.

Patient Guidance and Care Drives McCann’s Passion as a Woman in Oncology

March 20th 2025

Kelly E. McCann, MD, discusses mentorship in oncology and the importance of guiding patients with breast cancer through their treatment journey.

PEP-010 Wins FDA Orphan Drug Designation in Metastatic Pancreatic Cancer

March 20th 2025

PEP-010 has been granted an orphan drug designation by the FDA for the treatment of patients with metastatic pancreatic cancer.

FDA Grants Fast Track Designation to Azer-Cel for R/R DLBCL

March 20th 2025

The FDA granted fast track designation azercabtagene zapreleucel for relapsed/refractory diffuse large B-cell lymphoma.